Climb Bio, Inc. (Nasdaq: CLYM) Announces Pipeline Advances and Strategic Outlook for 2026
WELLESLEY HILLS, Mass., January 08, 2026 (GLOBE NEWSWIRE) – Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases, has unveiled significant advancements in its product pipeline, including updates on budoprutug and CLYM116. The company has outlined its strategic priorities for 2026 and revised its financial projections, positioning itself for a pivotal year ahead.
Highlights of Pipeline Progress
- First patients have been dosed in the budoprutug Phase 2 trial for Primary Membranous Nephropathy (pMN), with preliminary data anticipated in the second half of 2026.
- Ongoing dosing in the Phase 1b/2a trial for Immune Thrombocytopenia (ITP) and the Phase 1b trial for Systemic Lupus Erythematosus (SLE).
- CLYM116 Phase 1 healthy volunteer study has commenced.
- Financial strength indicated by a cash runway expected to sustain operations into 2028.
Revised Outlook for 2026
Dr. Aoife Brennan, M.B., Ch.B., President and CEO of Climb Bio, stated, “Reflecting on 2025, we aimed high and achieved substantial progress across clinical development and corporate objectives.” She emphasized the robust evaluations set for budoprutug, noting the initiation of four clinical trials and the successful clearance of the investigational new drug (IND) application in China.
Dr. Brennan further commented, “2026 promises to be transformative for Climb, with initial readouts from all ongoing trials on the horizon. Our diverse pipeline targeting multiple indications emphasizes our commitment to addressing unmet needs in renal and B-cell mediated diseases.”
2025 Major Achievements and Current Pipeline Status
Budoprutug: Anti-CD19 Monoclonal Antibody
- Phase 2 Trial in pMN: First Patient In (FPI) achieved in November 2025.
- Designed to evaluate safety, pharmacodynamics, and preliminary efficacy with hopes to identify a therapeutic dose for Phase 3 trials.
CLYM116: Anti-APRIL Monoclonal Antibody
- Exclusive license secured from Beijing Mabworks for CLYM116, extending its potential commercialization outside Greater China.
- Initiation of Phase 1 clinical trial for CLYM116, focusing on safety and efficacy.
Financial and Corporate Updates
Climb Bio has notably expanded its leadership team, appointing industry veterans to bolster its strategic direction. The board has been refreshed with experts such as Kim Cobleigh Drapkin, CPA, and Bo Cumbo. Moreover, Climb Bio's financial guidance has been updated, indicating available cash and equivalents are projected to support operations through 2028.
Key Anticipated Milestones for 2026
- budoprutug: SC formulation Phase 1 – Initial data expected in H1 2026.
- China SLE Phase 1b – First patient dosed in H1 2026.
- PrisMN (pMN) Phase 2 – Initial data anticipated in H2 2026.
- ITP Phase 1b/2a – Preliminary efficacy data expected in H2 2026.
- SLE Phase 1b – Initial efficacy data projected for H2 2026.
- CLYM116 Phase 1 – Expect initial data from the healthy volunteer study by mid-2026.
About Climb Bio, Inc.
Climb Bio, Inc. specializes in developing innovative therapeutics targeting immune-mediated diseases. Its leading pipeline candidates include budoprutug, an anti-CD19 monoclonal antibody for B-cell related conditions, and CLYM116, an anti-APRIL monoclonal antibody aimed at treating IgA nephropathy. For more information, visit climbbio.com.